More about

Atrial Fibrillation

News
November 28, 2023
2 min read
Save

News you may have missed from AHA 2023: SELECT, artificial intelligence, gene editing, more

News you may have missed from AHA 2023: SELECT, artificial intelligence, gene editing, more

Healio | Cardiology Today compiled a list of the top news from the 2023 American Heart Association Scientific Sessions.

News
November 28, 2023
3 min read
Save

Adhesive-based wearable cardioverter defibrillator beats performance goals

Adhesive-based wearable cardioverter defibrillator beats performance goals

PHILADELPHIA — A novel adhesive-based wearable cardioverter defibrillator was associated with high rates of patient compliance and low rates of adverse events, researchers reported at the American Heart Association Scientific Sessions.

News
November 27, 2023
1 min read
Save

LAA exclusion system for use in AF during cardiac surgery cleared, launched in US

LAA exclusion system for use in AF during cardiac surgery cleared, launched in US

Medtronic announced the U.S. launch of its left atrial appendage exclusion system for use during cardiac surgery in patients with preoperative atrial fibrillation.

News
November 27, 2023
3 min read
Save

Physical activity and atrial fibrillation: Where’s the balance?

Physical activity and atrial fibrillation: Where’s the balance?

Atrial fibrillation is a common arrhythmia that increases risk for stroke, HF and dementia. Although AF risk increases with age, it can also occur in young people with normal hearts, sometimes called “lone AF.”

News
November 14, 2023
2 min read
Save

In AF hospitalization, more than 10% of DOAC doses off-label after discharge

In AF hospitalization, more than 10% of DOAC doses off-label after discharge

PHILADELPHIA — Among patients hospitalized with atrial fibrillation discharged on a direct oral anticoagulant, more than 10% received an off-label dose, researchers reported at the American Heart Association Scientific Sessions.

News
November 12, 2023
4 min read
Save

Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial

Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial

PHILADELPHIA — In a phase 2b trial, abelacimab, a novel factor XI inhibitor, drastically reduced bleeding compared with rivaroxaban in patients with atrial fibrillation requiring stroke prevention.

News
November 12, 2023
3 min read
Save

In patients with subclinical AF, apixaban reduces stroke risk, raises bleeding risk

In patients with subclinical AF, apixaban reduces stroke risk, raises bleeding risk

PHILADELPHIA — In patients with subclinical atrial fibrillation, apixaban lowered risk for stroke but increased risk for bleeding compared with aspirin, according to the results of the ARTESIA trial.

News
November 10, 2023
2 min read
Save

What you may have missed from TCT 2023

What you may have missed from TCT 2023

Healio and Cardiology Today have aggregated news you may have missed from TCT 2023 in San Francisco.

News
October 25, 2023
3 min read
Save

SWISS-APERO at 1 year: LAA closure outcomes similar for Amulet, Watchman devices

SWISS-APERO at 1 year: LAA closure outcomes similar for Amulet, Watchman devices

SAN FRANCISCO — One-year data from the SWISS-APERO study show similar clinical outcomes and rates of patent left atrial appendages for patients undergoing LAA closure with either the Amulet or Watchman FLX devices, a speaker reported.

News
October 24, 2023
3 min read
Save

Concomitant left atrial appendage occlusion, TAVR an option for some with AF: WATCH-TAVR

Concomitant left atrial appendage occlusion, TAVR an option for some with AF: WATCH-TAVR

SAN FRANCISCO — Left atrial appendage occlusion at the time of transcatheter aortic valve replacement provides a noninferior treatment option to TAVR plus medical therapy in patients with severe aortic stenosis and atrial fibrillation.

View more